Xofigo ( or its generic trade name radium – 223 dicholoride ) is an FDA approved cancer drug treatment for patients who have a late stage prostate cancer that has spread to the patient’s bones, but not to other organs, such as the liver, the brain or the lungs.
Produced by Bayer Healthcare Pharmaceuticals, Inc., this cancer treatment is intended for patients whose advanced prostate cancer is also resistant to medical, or surgical, treatments to lower their testosterone levels.
Since testosterone may enable the prostate cancer to grow, the goal of some cancer surgery and drug treatments is to lower the amount of this male hormone in the patient’s body. When the cancer spreads or comes back after such treatments, it is sometimes referred to as castration resistant.
This treatment is also intended for patients who have symptomatic bone metastases and no known visceral metastatic disease. Symptomatic bone metastases means that the patient experiences pain within the bones that is not easily controlled with pain medication. And visceral metastatic disease is when the prostate cancer has spread to the patient’s organs such as liver, lungs or the brain.